1 / 1
Capmatinib(Tabrecta)
Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection
Reference price:
Manufacturer:
Novartis
Formulation:
TABLET
Validity period:
24 months
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of
a
pharmacist. For read by medical and pharmaceutical professionals only.
Tabrecta(Capmatinib) Instructions:Uses,Dosage, Side Effects
TABRECTA, with the generic name Capmatinib, is a targeted kinase inhibitor therapy. Its active pharmaceutical ingredient is capmatinib, formulated as film-coated tablets available in 150 mg and 200 mg strengths. The drug is specifically designed to target and inhibit the MET kinase, including the mutant variant caused by MET exon 14 skipping. This mutation leads to dysregulated MET signaling and drives cancer growth. TABRECTA is manufactured and distributed by Novartis Pharmaceuticals Corporation for oral administration in eligible adult patients.
